Evidence map›Paper›PMID 26428460›Full record

ArticleBMC genetics2015

Coronary risk in relation to genetic variation in MEOX2 and TCF15 in a Flemish population.

Wen-Yi Yang, Thibault Petit, Lutgarde Thijs, Zhen-Yu Zhang, Lotte Jacobs, Azusa Hara, Fang-Fei Wei, Erika Salvi, Lorena Citterio, Simona Delli Carpini and 13 more

Open access · diamondAbstract read
In one paragraph

Article in BMC genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 3 countries.

Wen-Yi YangResearch Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Kapucijnenvoer 35, Box 7001, BE-3000, Leuven, Belgium. wenyi.yang@med.kuleuven.be.
Thibault PetitResearch Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Kapucijnenvoer 35, Box 7001, BE-3000, Leuven, Belgium. thibault.petit@med.kuleuven.be.
Lutgarde ThijsResearch Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Kapucijnenvoer 35, Box 7001, BE-3000, Leuven, Belgium. lutgarde.thijs@med.kuleuven.be.
Zhen-Yu ZhangResearch Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Kapucijnenvoer 35, Box 7001, BE-3000, Leuven, Belgium. zhenyu.yang@med.kuleuven.be.
Lotte JacobsResearch Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Kapucijnenvoer 35, Box 7001, BE-3000, Leuven, Belgium. lotte.jacobs@med.kuleuven.be.
Azusa HaraResearch Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Kapucijnenvoer 35, Box 7001, BE-3000, Leuven, Belgium. aszussa@gmail.com.
Fang-Fei WeiResearch Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Kapucijnenvoer 35, Box 7001, BE-3000, Leuven, Belgium. fangfei.wei@med.kuleuven.be.
Erika SalviGenomics and Bioinformatics Platform at Filarete Foundation, Department of Health Sciences and Graduate School of Nephrology, Division of Nephrology, San Paolo Hospital, University of Milan, Milan, Italy. erika.salvi@unimi.it.
Lorena CitterioDivision of Nephrology and Dialysis, IRCCS San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy. citterio.lorena@hsr.it.
Simona Delli CarpiniDivision of Nephrology and Dialysis, IRCCS San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy. simona.dellicarpini@hsr.it.
Yu-Mei GuResearch Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Kapucijnenvoer 35, Box 7001, BE-3000, Leuven, Belgium. yumei.Gu@med.kuleuven.be.
Judita KnezResearch Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Kapucijnenvoer 35, Box 7001, BE-3000, Leuven, Belgium. Judita.Knez@med.kuleuven.be.
Nicholas CauwenberghsResearch Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Kapucijnenvoer 35, Box 7001, BE-3000, Leuven, Belgium. nicholas.cauwenberghs@student.kuleuven.be.
Matteo BarcellaGenomics and Bioinformatics Platform at Filarete Foundation, Department of Health Sciences and Graduate School of Nephrology, Division of Nephrology, San Paolo Hospital, University of Milan, Milan, Italy. matteo.barcella@unimi.it.
Cristina BarlassinaGenomics and Bioinformatics Platform at Filarete Foundation, Department of Health Sciences and Graduate School of Nephrology, Division of Nephrology, San Paolo Hospital, University of Milan, Milan, Italy. cristina.barlassina@unimi.it.
Paolo ManuntaSchool of Nephrology, University Vita-Salute San Raffaele, Milan, Italy. manunta.paolo@hsr.it.
Giulia CoppielloCentre for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium. giulia.coppiello@gmail.com.
Xabier L ArangurenCentre for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium. xlaranguren@unav.es.
Tatiana KuznetsovaResearch Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Kapucijnenvoer 35, Box 7001, BE-3000, Leuven, Belgium. tatiana.kouznetsova@med.kuleuven.be.
Daniele CusiGenomics and Bioinformatics Platform at Filarete Foundation, Department of Health Sciences and Graduate School of Nephrology, Division of Nephrology, San Paolo Hospital, University of Milan, Milan, Italy. daniele.cusi@unimi.it.
Peter VerhammeCentre for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium. peter.verhamme@uzleuven.be.
Aernout LuttunCentre for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium. aernout.luttun@med.kuleuven.be.
Jan A StaessenResearch Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Kapucijnenvoer 35, Box 7001, BE-3000, Leuven, Belgium. jan.staessen@med.kuleuven.be.
KU Leuven · BEUniversity of Milan · ITVita-Salute San Raffaele University · ITFondazione Filarete · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITMaastricht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn mice MEOX2/TCF15 heterodimers are highly expressed in heart endothelial cells and are involved in the transcriptional regulation of lipid transport. In a general population, we investigated whether genetic variation in these genes predicted coronary heart disease (CHD).

resultsIn 2027 participants randomly recruited from a Flemish population (51.0 % women; mean age 43.6 years), we genotyped six SNPs in MEOX2 and four in TCF15. Over 15.2 years (median), CHD, myocardial infarction, coronary revascularisation and ischaemic cardiomyopathy occurred in 106, 53, 78 and 22 participants. For SNPs, we contrasted CHD risk in minor-allele heterozygotes and homozygotes (variant) vs. major-allele homozygotes (reference) and for haplotypes carriers (variant) vs. non-carriers. In multivariable-adjusted analyses with correction for multiple testing, CHD risk was associated with MEOX2 SNPs (P ≤ 0.049), but not with TCF15 SNPs (P ≥ 0.29). The MEOX2 GTCCGC haplotype (frequency 16.5 %) was associated with the sex- and age-standardised CHD incidence (5.26 vs. 3.03 events per 1000 person-years; P = 0.036); the multivariable-adjusted hazard ratio [HR] of CHD was 1.78 (95 % confidence interval, 1.25-2.56; P = 0.0054). For myocardial infarction, coronary revascularisation, and ischaemic cardiomyopathy, the corresponding HRs were 1.96 (1.16-3.31), 1.87 (1.20-2.91) and 3.16 (1.41-7.09), respectively. The MEOX2 GTCCGC haplotype significantly improved the prediction of CHD over and beyond traditional risk factors and was associated with similar population-attributable risk as smoking (18.7 % vs. 16.2 %).

conclusionsGenetic variation in MEOX2, but not TCF15, is a strong predictor of CHD. Further experimental studies should elucidate the underlying molecular mechanisms.

Indexed as

Genetic VariationAdultBasic Helix-Loop-Helix ProteinsBelgiumComorbidityCoronary Artery DiseaseEthnicityFemaleGenotypeHaplotypesHomeodomain ProteinsHumansIncidenceMaleMiddle AgedPolymorphism, Single NucleotideBasic Helix-Loop-Helix ProteinsHomeodomain ProteinsMEOX2 protein, humanTCF15 protein, human

Identifiers

PMID26428460
PMCPMC4591634
OpenAlexW2167091089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.